NASVD News Alert National Automation Services Inc. (NASVD) 1.2900

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
National Automation Services Inc. (NASVD) 1.2900 $NASVD

National Automation Services, Inc. - Announces Engagement of New SEC Counsel
Marketwired - Tue Feb 03, 7:32AM CST
National Automation Services, Inc. ("NAS" or "Company" (OTCQB: NASV) a small, but rapidly growing oil and gas services company announced that it has engaged the services of Sichenzia, Ross, Friedman, Ference, LLP located at 61 Broadway, New York, NY 10006, as our new securities counsel.

JD Field Services Announces Banner December in Gross Revenues
Marketwired - Wed Jan 28, 7:31AM CST
National Automation Services, Inc. ("NAS" or "Company" (OTCQB: NASV) a small, but rapidly growing oil and gas services company announced that it projects that its subsidiary, JD Field Services ("JD" , is presently experiencing phenomenal growth, despite the current environment in the oil and gas sector. December 2014 gross revenues are expected to be a robust $2.5 Million, compared with $1.6 Million during the same period in 2013, and we project that this increased activity has carried into January for the first quarter of 2015.

JD Field Services Announces Purchase of New $2 Million Crane
Marketwired - Wed Jan 21, 7:30AM CST
National Automation Services, Inc. ("NAS" (OTCQB: NASV) a small, but rapidly growing oil and gas services company reported that its subsidiary JD Field Services continues to see significant opportunities for its services and believes the general slowing of the Oil and Gas exploration and drilling activity caused by the unprecedented drop in recent oil prices is providing robust demand in its field services.

National Automation Services, Inc. -- Letter to Shareholders
Marketwired - Mon Dec 15, 7:31AM CST
National Automation Services, Inc. ("NAS" (OTCQB: NASV) a small, but rapidly growing oil and gas services company has issued this informational letter to National Automation Services shareholders, which does not constitute an offer or invitation to sell, purchase or subscribe for any securities, or the solicitation of an offer to buy or subscribe for securities, in any jurisdiction and is not a prospectus as defined by the US Securities and Exchange Commission.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading